| |
original article |
Journal |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
Uirusu |
2025―Sep―28 |
Effects of aging and inflammation on antigen-specific CD8+ T-cell responses that protect against severe disease following SARS-CoV-2 infection","加齢と炎症がSARS-CoV-2感染後の重症化抑制に働く抗原特異的CD8+ T細胞応答に及ぼす影響 |
Takuto NOGIMORI, Takuya YAMAMOTO |
| 2 |
[GO] |
Uirusu |
2025―Feb―28 |
Creation of enveloped viral replica equipped with SARS-CoV2 spike protein","SARS-CoV-2由来スパイクタンパク質を搭載したエンベロープ型ウイルスレプリカの化学的創製 |
Kazunori MATSUURA, Hiroto FURUKAWA |
| 3 |
[GO] |
Uirusu |
2024―Nov―28 |
Control of infectious virus shedding through mucosal antibody response following SARS-CoV-2 infection","SARS-CoV-2に対する粘膜抗体応答による感染性ウイルス排出の制御 |
Sho MIYAMOTO, Tadaki SUZUKI |
| 4 |
[GO] |
Uirusu |
2024―Nov―28 |
Development of human iPS cell-derived alveolar and airway models using micropatterning plate for SARS-CoV-2 research","マイクロパターン培養プレートを用いたヒトiPS 細胞由来肺胞・気道モデルの開発とSARS-CoV-2 研究への応用 |
Rina HASHIMOTO, Atsushi MASUI, Shimpei GOTOH, Kazuo TAKAYAMA |
| 5 |
[GO] |
Uirusu |
2024―Nov―28 |
Characterization of SARS-CoV-2 variants using mini-gut organoids","「ミニ腸」を用いたSARS-CoV-2変異株の性状解析と今後の展開 |
Kei MIYAKAWA |
| 6 |
[GO] |
Uirusu |
2024―Sep―26 |
Development of an engineered ACE2 decoy for COVID-19 therapy.","ACE2デコイを用いた新型コロナウイルスに対する治療薬の開発 |
Toru OKAMOTO, Yumi ITOH, Tatsuya SUZUKI |
| 7 |
[GO] |
Uirusu |
2024―Sep―26 |
Neutralizing antibodies against SARS-CoV-2","新型コロナウイルスの中和抗体 |
Saya MORIYAMA |
| 8 |
[GO] |
Uirusu |
2024―Sep―26 |
SARS-CoV-2-specific T cell recognition toward emerging variants","新型コロナウイルス特異的T細胞の懸念すべき変異株に対する抗原認識機構 |
Chihiro MOTOZONO |
| 9 |
[GO] |
Uirusu |
2023―Oct―26 |
わが国におけるCOVID-19に対する免疫ランドスケープの構築","Grasping COVID-19 immune landscape in Japan |
Misaki SASANAMI, Hiroshi NISHIURA |
| 10 |
[GO] |
Uirusu |
2023―Oct―26 |
新型コロナウイルス感染症研究のデジタルトランスフォーメーション","Digital transformation of COVID-19 research |
Hyeongki Park, Joo Hyeon Woo, Shoya IWANAMI, Shingo IWAMI |
| 11 |
[GO] |
Uirusu |
2023―May―26 |
Infection prevention and control for COVID-19 in healthcare settings","新型コロナウイルス感染症（COVID-19）の感染対策 |
|
| 12 |
[GO] |
Uirusu |
2023―May―26 |
Infectivity-enhancing antibodies against SARS-CoV-2","SARS-CoV-2に対する感染増強抗体 |
|
| 13 |
[GO] |
Uirusu |
2022―May―02 |
Development, rollout, and challenges of COVID-19 vaccines in Japan and globally |
Takeshi ARASHIRO, Tadaki SUZUKI |
| 14 |
[GO] |
Uirusu |
2022―May―02 |
Dengue amidst COVID-19: challenges & control measures for the double burden |
Meng Ling Moi |
| 15 |
[GO] |
Uirusu |
2022―May―02 |
The innate immune response to SARS-CoV-2 |
Ken TAKASHIMA, Hiroyuki OSHIUMI |
| 16 |
[GO] |
Uirusu |
2022―May―02 |
Genomics and epidemiology of SARS-CoV-2 lineage |
Sayaka SUKEGAWA, Hiroaki TAKEUCHI |
| 17 |
[GO] |
Uirusu |
2021―Sep―17 |
Pathology and Immunology of COVID-19 |
Shun IIDA, Tadaki SUZUKI |
| 18 |
[GO] |
Uirusu |
2021―Sep―17 |
Basis of coronavirus infection, and SARS-CoV-2 |
Kazuya SHIRATO |
| 19 |
[GO] |
Uirusu |
2021―Sep―17 |
SARS-CoV-2 genomics and its application to genome surveillance |
Makoto KURODA |
| 20 |
[GO] |
Uirusu |
2021―May―07 |
COVID-19: From a clinician's perspective. |
Satoshi KUTSUNA |
| 21 |
[GO] |
Uirusu |
2021―May―07 |
Basic information of Coronavirus |
Wataru KAMITANI |
